These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9727891)

  • 41. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
    Foot EA; Eastmond R
    Diabetes Res Clin Pract; 1997 Oct; 38(1):41-51. PubMed ID: 9347245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
    Prigeon RL; Kahn SE; Porte D
    J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
    Schuster D; Gaillard T; Rhinesmith S; Habash D; Osei K
    Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
    Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
    Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
    N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
    Kuzuya T; Iwamoto Y; Kosaka K; Takebe K; Yamanouchi T; Kasuga M; Kajinuma H; Akanuma Y; Yoshida S; Shigeta Y
    Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.
    Iwamoto Y; Kuzuya T; Matsuda A; Awata T; Kumakura S; Inooka G; Shiraishi I
    Diabetes Care; 1991 Nov; 14(11):1083-6. PubMed ID: 1797492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
    Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
    Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
    Yatagai T; Nakamura T; Nagasaka S; Kusaka I; Ishikawa SE; Yoshitaka A; Ishibashi S
    Diabetes Res Clin Pract; 2004 Jan; 63(1):19-26. PubMed ID: 14693409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
    Buysschaert M; Bobbioni E; Starkie M; Frith L
    Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
    Osende JI; Badimon JJ; Fuster V; Herson P; Rabito P; Vidhun R; Zaman A; Rodriguez OJ; Lev EI; Rauch U; Heflt G; Fallon JT; Crandall JP
    J Am Coll Cardiol; 2001 Nov; 38(5):1307-12. PubMed ID: 11691500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
    Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
    Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
    Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.